Real-world evidence of novel treatments for COVID-19 on mortality: a nationwide comparative cohort study of hospitalized patients in the 1st, 2nd, 3rd and 4th wave in the Netherlands

Share

Open Forum Infectious Diseases

Background

Large clinical trials on drugs for hospitalized COVID-19 patients have shown significant effects on mortality. There may be a discrepancy with the observed real-world effect. We describe the clinical characteristics and outcomes of hospitalized COVID-19 patients in the Netherlands during four pandemic waves, and analyze the association of the newly introduced treatments with mortality, ICU-admission, and discharge alive.

Methods

We conducted a nationwide retrospective analysis of hospitalized COVID-19 patients between 27 February 2020 and 31 December 2021. Patients were categorized into waves and into treatment groups (hydroxychloroquine, remdesivir, neutralizing SARS-CoV-2 mAb, corticosteroids, and IL-6 antagonists). Four types of Cox-regression analyses were used: unadjusted, adjusted, propensity matched, and propensity weighted.

Results

Among 5643 patients from 11 hospitals we observed a changing epidemiology during four pandemic waves, with a decrease in median age (67 to 64 years, p < 0.001), in in-hospital mortality on the ward (21% to 15%, p < 0.001), and a trend on the ICU (24% to 16%, p = 0.148). In ward patients, hydroxychloroquine was associated with increased mortality (1.54 (95% CI 1.22-1.96)); remdesivir with a higher rate of discharge alive within 29 days (1.16 (95% CI 1.03-1.31)). Corticosteroids were associated with a decrease in mortality (0.82 (95% CI 0.69-0.96); the results of IL-6 antagonists were inconclusive. In patients directly admitted to the ICU, hydroxychloroquine, corticosteroids, and IL-6 antagonists were not associated with decreased mortality.

Conclusions

Both remdesivir and corticosteroids were associated with better outcomes in ward patients with COVID-19. Continuous evaluation of real-world treatment effects is needed.

Read full article here